EE200300587A - Vedel farmatseutiline kompositsioon, selle valmistamise meetod ja kasutamine - Google Patents

Vedel farmatseutiline kompositsioon, selle valmistamise meetod ja kasutamine

Info

Publication number
EE200300587A
EE200300587A EEP200300587A EEP200300587A EE200300587A EE 200300587 A EE200300587 A EE 200300587A EE P200300587 A EEP200300587 A EE P200300587A EE P200300587 A EEP200300587 A EE P200300587A EE 200300587 A EE200300587 A EE 200300587A
Authority
EE
Estonia
Prior art keywords
preparation
pharmaceutical composition
liquid pharmaceutical
liquid
composition
Prior art date
Application number
EEP200300587A
Other languages
English (en)
Estonian (et)
Inventor
Mahesh Kulkarni Neema
Schneider Michael
Bernard Silbering Steven
Richard Meyer-Wonnay Hans
Sanii-Yahyai Nahid
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200300587(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of EE200300587A publication Critical patent/EE200300587A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
EEP200300587A 2001-05-25 2002-04-29 Vedel farmatseutiline kompositsioon, selle valmistamise meetod ja kasutamine EE200300587A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29383201P 2001-05-25 2001-05-25
US34373301P 2001-10-25 2001-10-25
PCT/IB2002/001500 WO2002094220A1 (en) 2001-05-25 2002-04-29 Liquid pharmaceutical composition

Publications (1)

Publication Number Publication Date
EE200300587A true EE200300587A (et) 2004-02-16

Family

ID=26968180

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300587A EE200300587A (et) 2001-05-25 2002-04-29 Vedel farmatseutiline kompositsioon, selle valmistamise meetod ja kasutamine

Country Status (43)

Country Link
US (2) US20020198261A1 (sr)
EP (1) EP1395242B1 (sr)
JP (1) JP2004534764A (sr)
KR (1) KR100582963B1 (sr)
CN (1) CN100346779C (sr)
AP (1) AP1815A (sr)
AR (1) AR033922A1 (sr)
AT (1) ATE334656T1 (sr)
AU (1) AU2002258026B2 (sr)
BG (1) BG108376A (sr)
BR (1) BR0209973A (sr)
CA (1) CA2446574C (sr)
CR (1) CR7150A (sr)
CY (1) CY1105147T1 (sr)
CZ (1) CZ299755B6 (sr)
DE (1) DE60213592T2 (sr)
DK (1) DK1395242T3 (sr)
DO (1) DOP2002000403A (sr)
EA (1) EA008087B1 (sr)
EE (1) EE200300587A (sr)
EG (1) EG24078A (sr)
ES (1) ES2265040T3 (sr)
GE (1) GEP20053620B (sr)
HR (1) HRP20030833B1 (sr)
HU (1) HUP0401366A2 (sr)
IL (1) IL158359A0 (sr)
IS (1) IS2428B (sr)
MA (1) MA27026A1 (sr)
MX (1) MXPA03009392A (sr)
MY (1) MY128615A (sr)
NO (1) NO20035200D0 (sr)
NZ (1) NZ529173A (sr)
OA (1) OA12604A (sr)
PA (1) PA8545901A1 (sr)
PE (1) PE20030087A1 (sr)
PL (1) PL366384A1 (sr)
PT (1) PT1395242E (sr)
RS (1) RS87203A (sr)
SI (1) SI1395242T1 (sr)
SK (1) SK286227B6 (sr)
SV (1) SV2003001053A (sr)
WO (1) WO2002094220A1 (sr)
ZA (1) ZA200308393B (sr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934061B3 (en) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba and its derivatives for the treatment of pain
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
BR0313432A (pt) * 2002-08-15 2005-07-12 Pfizer Uso terapêutico de aminoácidos bicìclicos ou tricìclicos fundidos
EP2172197A1 (en) * 2002-12-13 2010-04-07 Warner-Lambert Company LLC Octanoic acid derivative to treat fibromyalgia and other pains
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
CA2510292A1 (en) * 2002-12-20 2004-07-15 Dynogen Pharmaceuticals, Inc. Methods of treating non-painful bladder disorders using .alpha.2.delta. subunit calcium channel modulators
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
ATE449633T1 (de) * 2003-09-12 2009-12-15 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
ATE526988T1 (de) * 2003-10-08 2011-10-15 Mallinckrodt Llc Methylphenidat-lösung und relevante verabreichungs- und herstellungsverfahren
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
US20050090549A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of pain
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102004015752B4 (de) * 2004-03-31 2007-04-05 Christian-Albrechts-Universität Zu Kiel Verwendung von Gabapentin-Laktam zur Behandlung renaler Erkrankungen
EP1806133A1 (en) * 2004-10-14 2007-07-11 Daikin Industries, Ltd. Method for modifying the ambience, and spray liquid and sprayer used in the method
CA2618474A1 (en) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for treating alzheimer's disease
EP1919861A2 (de) * 2005-08-11 2008-05-14 Boehringer Ingelheim International GmbH Verbindungen zur behandlung der alzheimer erkrankung
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
EP2246044A1 (en) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
TR201005241A1 (tr) * 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
WO2015144825A1 (en) * 2014-03-27 2015-10-01 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
CN104940930A (zh) * 2015-05-31 2015-09-30 黑龙江佰彤儿童药物研究有限公司 一种治疗儿童癫痫药物口服乳剂及其制备方法
WO2018167628A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
WO2019038584A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
WO2019186515A1 (en) * 2018-03-30 2019-10-03 Ftf Pharma Private Limited Liquid pharmaceutical compositions of antiepileptic drugs
WO2020039262A1 (en) 2018-08-18 2020-02-27 Ftf Pharma Private Limited Pharmaceuticals solution for oral dosage
GB2591396B (en) 2018-08-18 2023-06-07 Ftf Pharma Private Ltd Pharmaceutical suspension for oral dosage
US12083222B2 (en) 2018-08-18 2024-09-10 Oncosol Limited Chemotherapeutic pharmaceutical suspension for oral dosage
FI3946260T3 (fi) * 2019-03-26 2026-03-24 Orion Corp Pregabaliiniformulaatioita ja niiden käyttö
HU231397B1 (hu) 2021-01-22 2023-06-28 Egis Gyógyszergyár Zrt. Pregabalint tartalmazó topikális gyógyszerkészítmény
MX2023008647A (es) 2021-01-22 2023-08-01 Egyt Gyogyszervegyeszeti Gyar Formulacion topica que contiene pregabalina dispersada.
JPWO2022168968A1 (sr) * 2021-02-05 2022-08-11
CA3230309A1 (en) * 2021-08-31 2023-03-09 Jr. Samuel A. Testino Stable gabapentin powder
WO2024058812A1 (en) 2022-09-16 2024-03-21 Pyros Pharmaceuticals, Inc. Vigabatrin liquid pharmaceutical composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
CA2327285C (en) * 1998-05-15 2005-06-14 Warner-Lambert Company Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
KR20030059290A (ko) * 2000-11-30 2003-07-07 화이자 프로덕츠 인코포레이티드 Ｇａｂａ 작용제 및 소르비톨 데하이드로게나제 억제제의혼합물

Also Published As

Publication number Publication date
US20020198261A1 (en) 2002-12-26
SI1395242T1 (en) 2006-10-31
HRP20030833B1 (en) 2007-04-30
CR7150A (es) 2004-02-23
CA2446574C (en) 2008-04-01
EP1395242A1 (en) 2004-03-10
SV2003001053A (es) 2003-03-18
OA12604A (en) 2006-06-08
CZ20033066A3 (cs) 2004-08-18
PL366384A1 (en) 2005-01-24
NO20035200L (no) 2003-11-24
CZ299755B6 (cs) 2008-11-12
DK1395242T3 (da) 2006-10-30
MXPA03009392A (es) 2004-01-29
PT1395242E (pt) 2006-11-30
CN1509165A (zh) 2004-06-30
PA8545901A1 (es) 2003-09-05
AP2003002907A0 (en) 2003-12-31
KR20040003006A (ko) 2004-01-07
EP1395242B1 (en) 2006-08-02
CN100346779C (zh) 2007-11-07
ATE334656T1 (de) 2006-08-15
US20040072904A1 (en) 2004-04-15
EA200301152A1 (ru) 2004-04-29
KR100582963B1 (ko) 2006-05-24
MY128615A (en) 2007-02-28
AU2002258026B2 (en) 2007-08-02
ZA200308393B (en) 2005-04-26
SK286227B6 (sk) 2008-05-06
RS87203A (sr) 2006-10-27
ES2265040T3 (es) 2007-02-01
IL158359A0 (en) 2004-05-12
NZ529173A (en) 2005-07-29
DE60213592T2 (de) 2007-08-09
IS6986A (is) 2003-10-09
PE20030087A1 (es) 2003-02-14
WO2002094220A1 (en) 2002-11-28
AP1815A (en) 2008-01-04
CY1105147T1 (el) 2010-03-03
EA008087B1 (ru) 2007-02-27
AR033922A1 (es) 2004-01-07
CA2446574A1 (en) 2002-11-28
MA27026A1 (fr) 2004-12-20
BR0209973A (pt) 2004-04-06
IS2428B (is) 2008-10-15
HK1062646A1 (zh) 2004-11-19
NO20035200D0 (no) 2003-11-24
HRP20030833A2 (en) 2004-08-31
HUP0401366A2 (hu) 2004-11-29
DE60213592D1 (de) 2006-09-14
DOP2002000403A (es) 2002-11-30
GEP20053620B (en) 2005-09-26
JP2004534764A (ja) 2004-11-18
BG108376A (bg) 2005-04-30
US7256216B2 (en) 2007-08-14
SK14112003A3 (sk) 2004-08-03
EG24078A (en) 2008-05-11

Similar Documents

Publication Publication Date Title
EE200300236A (et) 1,2-difenüülasetidinoonid, nende kasutamine, ravim ja selle valmistamismeetod
EE200300581A (et) Karboksamiid-asendatud fenüüluurea derivaadid ja nende kasutamine, ravim ja selle valmistamismeetod
EE04464B1 (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE200300327A (et) Uurea derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutiline kompositsioon
EE200300369A (et) Atsüülitud indanüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat
DK1395242T3 (da) Flydende farmaceutisk sammensætning
EE200200487A (et) Asetidiini derivaadid, nende valmistamismeetodid ja farmatseutiline kompositsioon
EE05214B1 (et) Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
EE200300171A (et) Kristalliline monohüdraat, meetodid selle valmistamiseks ja selle kasutamine farmatseutilise kompositsiooni valmistamiseks
EE05475B1 (et) Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon
EE200300370A (et) Atsüülitud 6,7,8,9-tetrahüdro-5H-bensotsükloheptenüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat
EE200400028A (et) Ravimpreparaat, selle valmistamise meetod ja selle kasutamine meditsiinis
NO20031273L (no) Substituerte kanelsyreguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som legemiddel og legemiddel som inneholder de samme
EE200000596A (et) Tienüülasolüülalkoksüetaanamiinderivaadid, nende ja nende soolade valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja kasutamine ning vaheühend ja selle valmistamismeetod
IS6378A (is) Efnasambönd og samsetningar gegn dvergveirum, notkun þeirra til lyfjagerðar og efni til að framleiða þau
EE05175B1 (et) Asendatud bensimidasooli preparaat, meetod selle valmistamiseks ja selle kasutamine meditsiinis
PL394600A1 (pl) Związek winyloazacykloalkanowy, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna
EE200300488A (et) Lipiiditaset alandava toimega bifenüülkarboksamiidühend, meetod selle valmistamiseks ning seda sisaldav ravimkompositsioon
EE200300255A (et) Asitromütsiin monohüdraadina, selle valmistamismeetod ja selle kasutamine ravimkoostises
NO326689B1 (no) Pyrrolidinderivater, anvendelse derav, farmasøytisk preparat samt fremgangsmåte for fremstilling av forbindelsene
EE04346B1 (et) Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE05168B1 (et) N-guanidinoalklamiid, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning raviotstarbeline kasutamine
EE04902B1 (et) Mikrograanul, selle valmistamismeetod ja farmatseutiline preparaat
EE04855B1 (et) Hüübimistegurit pärssiv ühend, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaatning raviotstarbeline kasutamine
HUP0401369A3 (en) Pharmaceutical formulation comprising (r)-bicalutamide, process for its preparation and use thereof